Cost Of Revenue - NuVasive Inc (F:NK8) - Alpha Spread
N

NuVasive Inc
F:NK8

Watchlist Manager
NuVasive Inc
F:NK8
Watchlist
Price: 36.8 EUR Market Closed
Market Cap: 1.9B EUR
Have any thoughts about
NuVasive Inc?
Write Note

NuVasive Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

NuVasive Inc
Cost of Revenue Peer Comparison

Comparables:
BDX
BSX
SYK
ABT
ISRG

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
N
NuVasive Inc
F:NK8
Cost of Revenue
-$347.5m
CAGR 3-Years
-4%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
Becton Dickinson and Co
NYSE:BDX
Cost of Revenue
-$10.8B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
-10%
Boston Scientific Corp
NYSE:BSX
Cost of Revenue
-$4.7B
CAGR 3-Years
-8%
CAGR 5-Years
-10%
CAGR 10-Years
-8%
Stryker Corp
NYSE:SYK
Cost of Revenue
-$7.7B
CAGR 3-Years
-10%
CAGR 5-Years
-10%
CAGR 10-Years
-10%
Abbott Laboratories
NYSE:ABT
Cost of Revenue
-$18.2B
CAGR 3-Years
-1%
CAGR 5-Years
-7%
CAGR 10-Years
-7%
Intuitive Surgical Inc
NASDAQ:ISRG
Cost of Revenue
-$2.5B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-15%

See Also

What is NuVasive Inc's Cost of Revenue?
Cost of Revenue
-347.5m USD

Based on the financial report for Jun 30, 2023, NuVasive Inc's Cost of Revenue amounts to -347.5m USD.

What is NuVasive Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-8%

Over the last year, the Cost of Revenue growth was -3%. The average annual Cost of Revenue growth rates for NuVasive Inc have been -4% over the past three years , -4% over the past five years , and -8% over the past ten years .

Back to Top